Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Asia 2022 | Anbal-cel: Updated results from Phase I study of novel CD19-targeting CAR-T therapy

Won-Seog Kim • 24 Nov 2022
ESMO Asia 2022
General

Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses updated data on immune-related toxicities from the Phase I/II trial of Anbal-cel, a CD19-targeting CAR-T therapy. Phase II of the trial is currently ongoing. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Won-Seog Kim

1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023

Related Videos

1:13
The pitfalls in genomics for myeloid malignancies
Thomas Coats • 29 Apr 2024
3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals